MS Treatment (with Cycle Vita)
Multiple Sclerosis (MS)
CommercialActive
Key Facts
About Cycle Pharmaceuticals
Cycle Pharmaceuticals is a patient-centric, commercial-stage biopharma company specializing in rare and underserved diseases. It leverages a hybrid model of developing/acquiring treatments and wrapping them in its proprietary Cycle Vita™ patient support ecosystem, which provides clinical, dietary, and access services. The company is actively expanding its U.S. footprint through new product launches and strategic acquisitions, as evidenced by its 2026 tender offer for Applied Therapeutics, positioning it for growth in the high-need, high-value rare disease market.
View full company profileTherapeutic Areas
Other Multiple Sclerosis (MS) Drugs
| Drug | Company | Phase |
|---|---|---|
| SAR443820/DNL788 | Denali Therapeutics | Phase 2 |
| Therapeutic Program | Pasithea Therapeutics | Research |
| GM6 | Genervon Biopharmaceuticals | Planning |
| Cobratoxin-based Therapy | Nutra Pharma | Pre-clinical |
| MS Biomarker Development | Progentec Diagnostics | Pre-clinical/R&D |